Clinical Trial Update: fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder [Phase 1]

View source ↗

Summary

Phase 1 fMRI study examining BOLD activation patterns using GW679769 in individuals with Social Anxiety Disorder; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Social Anxiety Disorder

Drugs mentioned

• GW679769

Snippet

Sponsor: GlaxoSmithKline | Conditions: Social Anxiety Disorder | Phase 1 | Status: COMPLETED